Clinical trial · Observational
Umbrella Study for Single Patient Treatments in Oncology
UNIQUE: Umbrella N-of-1 Tumor Trials - Umbrella Protocol for Oncology Single Patient Protocols
NCT06285500CI-TRIAL-00098984UNIQUErecruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to collect data for assessing the improvement of the overall response rate for the overall cohorts and the proportion of patients accessing precision targeted therapy.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Advanced Cancer | Malignant Neoplasm | CURATED_BROADER | 0.78 |
| Rare Diseases | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Patient-specific treatments | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (3)
- label
- Group 1
- description
- N-of-1 treatment with marketed drugs used on or off-label as per SOC.
- interventionNames
- Other: Patient-specific treatments
- label
- Group 2
- description
- N-of-1 treatment with drugs accessed from SAP.
- interventionNames
- Other: Patient-specific treatments
- label
- Group 3
- description
- N-of-1 treatment with non-marketed investigational agents.
- interventionNames
- Other: Patient-specific treatments
Primary outcomes (1)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria \& Exclusion Criteria: Patient's existing genomic information from tumor molecular profiling will be discussed in the hospital expert molecular tumor board rounds consisting of representatives from specialist genomic profiling and medical oncology departments to decide N of 1 treatment for the patient. The discussion will surround the best next therapeutic option in the patient's cancer subtype with or without clear standard of care guidelines. Therefore, specific eligibility criteria aside from individual patient's medical history is not applicable.
References
Publications (0)
Data not yet available
No reference posted for this study.